The journal of headache and pain · 2026
Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nociti Viviana, Cesarano Simone, Romozzi Marina, Totaro Rocco, Albanese Maria, Casalena Alfonsina, Annovazzi Pietro, Fantozzi Roberta, Tortorella Carla, Vercellino Marco, Iannone Luigi Francesco, De Luca Giovanna, Tomassini Valentina, Di Filippo Massimiliano, Lorefice Lorena, Maniscalco Giorgia Teresa, Paolicelli Damiano, Pinardi Federica, Clerici Valentina Torri, Marfia Girolama Alessandra, Centonze Diego, Solaro Claudio Marcello, Gasperini Claudio, Calabresi Paolo, Mirabella Massimiliano, Vollono Catello, Cocco Eleonora, Pistoia Francesca
Аннотация
BACKGROUND: Migraine is common in people with multiple sclerosis (PwMS) and substantially contributes to disability and impaired quality of life. Although (CGRP)-targeting therapies have reshaped migraine prevention, evidence on their use in PwMS remains scarce, particularly in people receiving concomitant disease-modifying therapies (DMTs).
METHODS: We retrospectively collected data from 17 Italian multiple sclerosis (MS) centers on adult PwMS with comorbid migraine treated with anti-CGRP monoclonal antibodies or gepants in addition to stable DMTs. Monthly headache days (MHDs) and total number of analgesics per month were compared between treatment initiation and last follow-up. MS activity was assessed through clinical relapses, Expanded Disability Status Scale (EDSS), and MRI findings. A ≥ 50% reduction in MHDs defined treatment response. Multivariate regression models were used to explore predictors of response to anti-CGRP therapies.
RESULTS: Fifty-four patients were included (46 women; mean age 42.3 years; 85% relapsing MS). Baseline MHDs averaged 19.87 ± 6.97 and declined to 11.40 ± 9.35 at follow-up (p < 0.001), with a parallel decrease in analgesic use (p < 0.001). Responder rate at the last follow-up was 53.7%. MS disease activity remained stable, with no significant changes in relapse rate, EDSS score, or MRI activity. Higher baseline headache burden was associated with greater reduction in MHDs (β=+0.685, p < 0.001), whereas longer MS duration predicted poorer response (OR1.43, 95%CI 1.06-1.92, p = 0.016). Mild adverse events occurred in four patients (7%), without treatment discontinuation.
CONCLUSION: Anti-CGRP pathway therapies provided meaningful migraine improvement in PwMS while maintaining MS stability. MS disease duration and baseline headache frequency may influence therapeutic response to anti-CGRP drugs in PwMS.
CLINICAL TRIAL NUMBER: Not applicable.
METHODS: We retrospectively collected data from 17 Italian multiple sclerosis (MS) centers on adult PwMS with comorbid migraine treated with anti-CGRP monoclonal antibodies or gepants in addition to stable DMTs. Monthly headache days (MHDs) and total number of analgesics per month were compared between treatment initiation and last follow-up. MS activity was assessed through clinical relapses, Expanded Disability Status Scale (EDSS), and MRI findings. A ≥ 50% reduction in MHDs defined treatment response. Multivariate regression models were used to explore predictors of response to anti-CGRP therapies.
RESULTS: Fifty-four patients were included (46 women; mean age 42.3 years; 85% relapsing MS). Baseline MHDs averaged 19.87 ± 6.97 and declined to 11.40 ± 9.35 at follow-up (p < 0.001), with a parallel decrease in analgesic use (p < 0.001). Responder rate at the last follow-up was 53.7%. MS disease activity remained stable, with no significant changes in relapse rate, EDSS score, or MRI activity. Higher baseline headache burden was associated with greater reduction in MHDs (β=+0.685, p < 0.001), whereas longer MS duration predicted poorer response (OR1.43, 95%CI 1.06-1.92, p = 0.016). Mild adverse events occurred in four patients (7%), without treatment discontinuation.
CONCLUSION: Anti-CGRP pathway therapies provided meaningful migraine improvement in PwMS while maintaining MS stability. MS disease duration and baseline headache frequency may influence therapeutic response to anti-CGRP drugs in PwMS.
CLINICAL TRIAL NUMBER: Not applicable.